GlassScriptPhysician profile
Alyssa Jameson
NPI 1427410802
$64,870.49
in general payments reported to CMS, 2019-2025
49 companies · $65.52 in 2025
The $65.52 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36K · 2022: $28K · 2023: $808 · 2025: $65.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24,671.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12,892.87 | 2022 | |
| Abbvie INC. | $11,844.86 | 2021-2023 | |
| Biogen, INC. | $2,130.34 | 2021-2023 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $1,661.85 | 2021-2023 | Austedo |
| Neurocrine Biosciences, INC. | $1,543.76 | 2021-2023 | Ingrezza |
| Emd Serono, INC. | $1,189.22 | 2021-2023 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $987.83 | 2021-2023 | |
| Sk Life Science, INC. | $860.05 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $836.46 | 2021-2023 | Ultomiris |
| Amgen INC. | $570.29 | 2021-2022 | |
| Lilly USA, LLC | $491.95 | 2021-2022 | |
| Ucb, INC. | $461.32 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $429.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $394.89 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Jameson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.